COLL News and Press, Collegium Pharmaceutical Inc. From 08/24/23

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administrat...

2023-08-12 05:25:17 ET Summary Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing innovative treatments for chronic pain with abuse-deterrent technology. The company's financials show solid sales momentum, decreased operating expenses, improved pr...

2023-08-11 11:20:06 ET Summary Collegium Pharmaceutical presents attractive value for investors with a forward earnings multiple of 4.5x and a 30% return on capital deployed. Q2 earnings indicate potential for momentum and a target price of $33/share in my view. The stock has ...

2023-08-07 08:36:26 ET Collegium Pharmaceutical ( NASDAQ: COLL ) on Monday said it had entered into an Accelerated Share Repurchase agreement with Jefferies to repurchase $50M of the company’s common stock. Collegium will execute the ASR as part of the $100 million shar...

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated...

2023-08-04 16:50:24 ET Collegium Pharmaceutical, Inc. (COLL) Q2 2023 Earnings Conference Call August 03, 2023 04:30 PM ET Company Participants Christopher James - Vice President-Investor Relations Joe Ciaffoni – President & Chief Executive Officer Coll...

2023-08-03 16:14:51 ET Collegium Pharmaceutical press release ( NASDAQ: COLL ): Q2 Non-GAAP EPS of $1.26 beats by $0.04 . Revenue of $135.5M (+9.7% Y/Y) misses by $2.91M . Adjusted EBITDA for the 2023 Quarter was $85.8 million, compared to $71.2 million for the...

– Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2’23 GAAP Net Income of $13.0 Million – – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has Auth...

STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2023...

STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a f...